What does WENDUINE PHARMA do?

WENDUINE PHARMA is a logistics company in De Haan. Private Limited, started on 28 December 1983, 1 establishment.

What is the address of WENDUINE PHARMA?

The registered office of WENDUINE PHARMA is located at Kerkstraat 7, 8420 De Haan.

Is WENDUINE PHARMA still active?

Yes. According to the CBE (29 October 2026) WENDUINE PHARMA is active, legal situation “Normale toestand”, started on 28 December 1983.

Is WENDUINE PHARMA registered on Peppol?

Yes, WENDUINE PHARMA is registered on the Peppol network with ID 0208:0425384986.

What is the enterprise number of WENDUINE PHARMA?

The enterprise number of WENDUINE PHARMA is BE0425384986.

When was WENDUINE PHARMA founded?

WENDUINE PHARMA was founded on 28 December 1983.

Who are the directors of WENDUINE PHARMA?

According to the 2025 annual accounts, the directors of WENDUINE PHARMA are: Sodiap BV, Alexo BV.

Is WENDUINE PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 December 1983; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did WENDUINE PHARMA make in 2025?

WENDUINE PHARMA posted a profit after taxes of € 74,220 in financial year 2025.

What is the revenue of WENDUINE PHARMA?

As a small company, WENDUINE PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 368,996.

How much does an employee at WENDUINE PHARMA earn?

The average wage cost per full-time employee at WENDUINE PHARMA was € 64,500 in 2025: staff costs of € 193,385 for 3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does WENDUINE PHARMA have?

According to the 2025 annual accounts, WENDUINE PHARMA has 3 full-time equivalents (FTE).

WENDUINE PHARMA (Private Limited) - De Haan

Dossier WENDUINE PHARMA, printed on 29 October 2026 from databakkes.be/en/0425384986/wenduine-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

WENDUINE PHARMA from De Haan, company number BE0425384986, closed financial year 2025 with a result of € 74,220 after tax. For that financial year WENDUINE PHARMA recorded a gross margin of € 368,996 and equity of € 1.1 million. Compared with financial year 2024, the result moved from € 48,945 to € 74,220. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 12, 2026.

What it is worth Growing

€ 1.1 million

▲ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 74,220

▲ 52% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 4,749

▼ 11% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.1 million.

People and assets in 2025

Full-time equivalents

▼ 0.3 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 193,385

▲ 4% vs 2024

€ 64,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 3,481

▲ 151% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 124,972

▼ 11% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 40,319

▲ 53% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 140,759 Gross margin 2022: € 140,759 First fiscal year in the series	€ 169,129 Gross margin 2023: € 169,129 ▲ 20% vs 2022 (€ 140,759) Favourable step	€ 328,681 Gross margin 2024: € 328,681 ▲ 94% vs 2023 (€ 169,129) Favourable step	€ 368,996 Gross margin 2025: € 368,996 ▲ 12% vs 2024 (€ 328,681) Favourable step	▲ 12%
Profit after taxes	€ 25,543 Profit after taxes 2022: € 25,543 First fiscal year in the series	€ -54,409 Profit after taxes 2023: € -54,409 ▼ € 79,952 vs 2022 (€ 25,543) Unfavourable step	€ 48,945 Profit after taxes 2024: € 48,945 ▲ € 103,354 vs 2023 (€ -54,409) Favourable step	€ 74,220 Profit after taxes 2025: € 74,220 ▲ 52% vs 2024 (€ 48,945) Favourable step	▲ 52%
Equity	€ 1,457,399 Equity 2022: € 1,457,399 First fiscal year in the series	€ 958,990 Equity 2023: € 958,990 ▼ 34% vs 2022 (€ 1,457,399) Unfavourable step	€ 1,007,935 Equity 2024: € 1,007,935 ▲ 5% vs 2023 (€ 958,990) Favourable step	€ 1,082,155 Equity 2025: € 1,082,155 ▲ 7% vs 2024 (€ 1,007,935) Favourable step	▲ 7%
Total debts	€ 232,228 Total debts 2022: € 232,228 First fiscal year in the series	€ 243,408 Total debts 2023: € 243,408 ▲ 5% vs 2022 (€ 232,228) Unfavourable step	€ 166,340 Total debts 2024: € 166,340 ▼ 32% vs 2023 (€ 243,408) Favourable step	€ 165,291 Total debts 2025: € 165,291 ▼ 1% vs 2024 (€ 166,340) Favourable step	▼ 1%
Cash	€ 5,997 Cash 2022: € 5,997 First fiscal year in the series	€ 7,733 Cash 2023: € 7,733 ▲ 29% vs 2022 (€ 5,997) Favourable step	€ 5,339 Cash 2024: € 5,339 ▼ 31% vs 2023 (€ 7,733) Unfavourable step	€ 4,749 Cash 2025: € 4,749 ▼ 11% vs 2024 (€ 5,339) Unfavourable step	▼ 11%
Land & buildings	€ 509,661 Land & buildings 2022: € 509,661 First fiscal year in the series	€ 547,708 Land & buildings 2023: € 547,708 ▲ 7% vs 2022 (€ 509,661) Unchanged	€ 525,742 Land & buildings 2024: € 525,742 ▼ 4% vs 2023 (€ 547,708) Unchanged	€ 503,775 Land & buildings 2025: € 503,775 ▼ 4% vs 2024 (€ 525,742) Unchanged	▼ 4%
Retained profit	€ 1,438,799 Retained profit 2022: € 1,438,799 First fiscal year in the series	€ 940,390 Retained profit 2023: € 940,390 ▼ 35% vs 2022 (€ 1,438,799) Unfavourable step	€ 989,335 Retained profit 2024: € 989,335 ▲ 5% vs 2023 (€ 940,390) Favourable step	€ 1,063,555 Retained profit 2025: € 1,063,555 ▲ 8% vs 2024 (€ 989,335) Favourable step	▲ 8%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 444,000 Dividend 2023: € 444,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 444,000) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 1,689,627 Balance sheet total 2022: € 1,689,627 First fiscal year in the series	€ 1,202,398 Balance sheet total 2023: € 1,202,398 ▼ 29% vs 2022 (€ 1,689,627) Unchanged	€ 1,174,275 Balance sheet total 2024: € 1,174,275 ▼ 2% vs 2023 (€ 1,202,398) Unchanged	€ 1,247,446 Balance sheet total 2025: € 1,247,446 ▲ 6% vs 2024 (€ 1,174,275) Unchanged	▲ 6%
Employees (FTE)	2.1 Employees (FTE) 2022: 2.1 First fiscal year in the series	3.1 Employees (FTE) 2023: 3.1 ▲ 1 vs 2022 (2.1) Unchanged	3.3 Employees (FTE) 2024: 3.3 ▲ 0.2 vs 2023 (3.1) Unchanged	3 Employees (FTE) 2025: 3 ▼ 0.3 vs 2024 (3.3) Unchanged	▼ 0.3

Key figures of WENDUINE PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to WENDUINE PHARMA?

What happened at WENDUINE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 12, 2026 New annual accounts for financial year 2025: profit of € 74,220 (▲ 52% vs 2024). Source: NBB ↗
2022 Alexo BV became a director. NBB
2020 Sodiap BV became a director. NBB
Mar 1, 1984 New establishment in De Haan. KBO
Dec 28, 1983 Start of the company according to the CBE. KBO

In short

From € 25,543 profit in 2022 to € 74,220 profit in 2025.

Paid € 51,764 in corporate taxes since 2022.

Best year ever: 2025, with € 74,220 profit.

On average € 123,000 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

SODIAP 100%

The stake of SODIAP comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

WENDUINE PHARMA

Behind WENDUINE PHARMA are Sodiap BV and Alexo BV. The shares are held by SODIAP (100%).

Directors

According to the 2025 annual accounts

Sodiap BV

Managing director · represented by Tom Goderis

Also active at: SDC, HC Pharma, APOTHEEK JENNE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT, C.E. FARMA, SANIFAR +24 more

since 2020

Alexo BV

Chairman of the board · represented by Olivier Delaere

Also active at: SDC, HC Pharma, SODIAP, APOTHEEK JENNE, PANNOC CHEMIE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT +34 more

since 2022

Shareholders

SODIAP

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Kerkstraat 7

8420 De Haan

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0425.384.986

VAT number

BE 0425.384.986

Registered office

Kerkstraat 7, 8420 De Haan

Names & denominations

WENDUINE PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

28 December 1983

Peppol

Active · Active since 6 Jun 2025

Activities · NACE

Apothekers

Detailhandel in farmaceutische producten

Bemiddeling in verband met exploitatie van en handel in onroerend goed

Bemiddeling bij de aankoop, verkoop en verhuur van onroerend goed

Bemiddeling bij de aankoop, verkoop en verhuur van onroerend goed voor een vast bedrag of op contractbasis

View on CBE Public ↗ Annual accounts (NBB) ↗

WENDUINE PHARMA

Financials

What happened to WENDUINE PHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions